in the blood of patients with various diseases, including diabetes, cardiovascular diseases and cancers. [5] [6] [7] Our previous studies have shown that the level of circulating MVs (CMVs) in peripheral blood is significantly elevated in patients with OSCC compared to healthy donors, and it is positively correlated with the clinical features of OSCC patients. 8, 9 In addition to the plasma, increased levels of MVs have been reported in other types of body fluids, such as urine in patients with bladder cancer, 10 ascites in patients with ovarian carcinoma 11 and pleural fluids in patients with lung cancer. 12 Previous studies have confirmed that MVs are present in the saliva of healthy donors. 13 However, the change in salivary MVs (SMVs) during the development of OSCC is still unclear. Since the primary tumour is directly immersed in the salivary milieu in OSCC patients, tumour cells may potentially release MVs into the saliva. Moreover, previous studies have demonstrated that
MVs produced upon cell apoptosis (known as apoptotic MVs) or cell activation might possess different pathophysiological functions. [14] [15] [16] Because suppression of apoptosis plays an important role in the development of cancer, the level of apoptotic MVs, 17, 18 which is usually a reflection of the level of cell apoptosis, has been linked to the development of cancer. [19] [20] [21] For instance, a previous study showed that the level of apoptotic MVs in peripheral blood possessed diagnostic significance in lung cancer. 22 However, the biomarker potential of SMVs and apoptotic SMVs in OSCC patients remains to be clarified.
In the present study, the level of total SMVs and the proportion of apoptotic SMVs were evaluated and compared among healthy donors, patients with oral ulcer (OU) and patients with OSCC. In addition, the correlations of SMVs with the clinicopathologic features and prognosis of OSCC patients was examined.
| MATERIAL S AND ME THODS

| Isolation of SMVs and CMVs
This study was carried out according to the guidelines approved by the re- 
| Characterization and quantification of SMVs and CMVs
According to our previous studies, 8, 24 transmission electron microscopy (TEM), dynamic light scattering, carboxyfluorescein succinimidyl ester (CFSE) labeling and flow cytometry were first performed to characterize the purified SMVs and CMVs. Then, the concentrations of MVs were analysed by the count of "events" using flow cytometer. Briefly, identical volumes of a MV sample and the With regard to incubation buffers, Annexin V Binding Buffer containing calcium (BD Biosciences) was used for PE-labeled Annexin V, and PBS was used for other antibodies recognizing cellular origin markers.
| Immunohistochemistry
Based on previously described procedures, [26] [27] [28] the samples from OSCC patients were fixed in 4% paraformaldehyde and embedded in paraffin. Immunohistochemistry was performed as described in the supplementary materials.
| Statistical analysis
All data in our study were shown as Mean ± SD of three independent experiments. Student's t test, one-way analysis of variance and Spearman's rank correlation test were used for statistical analysis. A value of P < 0.05 was considered statistically significant.
| RE SULTS
| Clinical characteristics and follow-up of the patients with OSCC
In our present study, the age distribution and gender ratio were similar among the healthy donors, patients with OU and patients with OSCC, with no significant difference (P > 0.05). All cases of OSCC patients were free of any other systemic disease including diabetes and cardiovascular disorders. Up to April 2018, the 65 OSCC patients were followed up from 2 to 45 months. The overall survival rate was 84.6%, the disease-free survival rate was 76.9% and the recurrence rate was 21.5%. Figure 1C ). Additionally, the CFSE labeling assay showed that the purified SMVs could be successfully labeled by CFSE, indicating their membrane-bound structures ( Figure 1D ). The flow cytometric results further showed that the majority of particles within the SMV samples were positive for CFSE staining ( Figure 1E ), suggesting the purity of the isolated SMVs. These above data demonstrate that the purified SMVs are in line with the features of MVs, and some of the basic properties of SMVs, such as physical morphology, size distribution and zeta potential, are not significantly changed in OSCC patients.
| The level of SMVs is elevated in OSCC patients
For quantifying the SMVs and CMVs, flow cytometry using flowcount fluorospheres was performed. Representative images of flow cytometry for detecting SMVs and CMVs were shown in Figure 2A Figure 2F , the level of CMVs was significantly elevated in OSCC patients compared to healthy donors (P < 0.001).
Nevertheless, there was no significant correlation between the increased levels of SMVs and CMVs in OSCC patients ( Figure S3A ). In addition, our results revealed that the majority of OSCC-CMVs were CD31 + CD41b + platelet-derived MVs, while the majority of OSCCSMVs were positive for EpCAM, indicating the origin of epithelial cells ( Figure S3B ). These results demonstrate that the level of SMVs is elevated concomitant with the level of CMVs in patients with OSCC. However, the cellular origins of SMVs and CMVs in OSCC patients might be significantly different.
| Increased SMVs are correlated with the clinicopathologic features of OSCC patients
Next, associations between the elevated level of SMVs and the clinicopathologic features of OSCC patients were investigated. As shown in Figure 2D , the level of SMVs in OSCC patients with lymph node metastasis was markedly up-regulated compared to patients without lymph node metastasis (P < 0.01). Moreover, as shown in Figure 2G . The semi-quantitative results revealed that the expression level of VEGF-C in the tumour samples was markedly increased in the patients with higher levels of SMVs when compared to those with lower levels of SMVs ( Figure 2H ). Importantly, the correlation analysis showed that the intratumoral expression level of VEGF-C in OSCC patients was positively associated with the level of SMVs ( Figure 2I ). These above results suggest that the increased SMVs could be a potential biomarker of clinicopathologic features of OSCC patients.
| The ratio of apoptotic to non-apoptotic SMVs is decreased in patients with poorly differentiated OSCC
Annexin V has been frequently used as a marker of MVs from apoptotic cells, especially when analysing the MVs in human body fluids. 6, 29, 30 As shown in Figure 3A , the percentages of apoptotic Figure 3E ). These results suggest that the proportion of apoptotic SMVs is decreased while the proportion of non-apoptotic SMVs is increased in OSCC patients with a higher pathological grade. Correspondingly, as shown in Figure 3F , the ratio of Annexin V + to Annexin V − OSCC-SMVs had a negative correlation with pathological grade (P < 0.01). These above data demonstrate that the ratio of apoptotic to non-apoptotic OSCCSMVs is decreased in poorly differentiated OSCC, suggesting that the formation mechanism of SMVs in terms of apoptosis is altered during the malignant progression of OSCC.
| Prognostic significance of SMVs in OSCC patients
To further determine the prognostic values of SMVs, patients with OSCC were divided into two groups based on either the level of OSCC-SMVs or the ratio of Annexin V + to Annexin V − SMVs.
Kaplan-Meier analysis revealed that the overall survival, diseasefree survival and recurrence-free survival curves stratified but showed no significant difference according to the level of total OSCC-SMVs ( Figure 4A-C) . Also, these survival curves stratified based on the ratio of Annexin V + to Annexin V − OSCC-SMVs ( Figure 4D-F) . With a statistical significance, OSCC patients with a higher ratio of Annexin V + to Annexin V − OSCC-SMVs were predicted to have a better outcome in terms of overall survival (P < 0.05). These above results suggest the prognostic value and biomarker potential of SMVs, especially the ratio of Annexin V + to Annexin V − SMVs.
| D ISCUSS I ON
Previous studies have showed that the level of MVs, which are submicron (100-1000 nm) membrane vesicles released by cells upon apoptosis or activation, is elevated in various human body fluids due to the development of malignant tumours. 11, 31, 32 Although the presence of MVs in saliva of healthy donors has been reported by a previous study, 13 the association between SMVs and OSCC is still unknown. In the present study, we find that the level of SMVs is significantly up-regulated in patients with OSCC compared to healthy donors and OU patients. Meanwhile, the level of SMVs shows positive correlation with the clinicopathologic features of OSCC patients. Moreover, the ratio of Annexin V + to Annexin V − SMVs, which represents the ratio of apoptotic SMVs and non-apoptotic SMVs, is significantly decreased in patients with poorly differentiated OSCC. More importantly, OSCC patients with higher ratio of apoptotic to non-apoptotic SMVs show better overall survival than patients with lower ratio of apoptotic to non-apoptotic SMVs.
Recently, our studies have shown that the level of CMVs is elevated and closely associated with the increased procoagulant activity and tumour angiogenesis in OSCC patients. 8, 9 Here, we found that the major subpopulations and the formation mechanism (in terms of apoptosis) of SMVs and CMVs in OSCC patients were different. CMVs derived from OSCC patients were almost platelet-derived MVs, while more than 50% of SMVs derived from OSCC patients showed epithelial origin. Moreover, consistent with a previous report, 33 we found that the majority of CMVs derived from OSCC patients were negative for Annexin V staining (indicative of It has been widely accepted that both cell apoptosis and activation can result in the generation of MVs. 29 To investigate the clinical significance of SMVs in terms of apoptosis in OSCC patients, we performed Annexin V staining by flow cytometry, which has been widely used to distinguish between apoptotic (Annexin V + ) and nonapoptotic (Annexin V − ) MVs. 6, 14, 34 We found that the ratio of apoptotic to non-apoptotic SMVs possessed a negative correlation with the pathological grade in OSCC patients, and OSCC patients with lower ratio of apoptotic to non-apoptotic SMVs were predicted to have a worse prognosis. These data suggest that SMVs may be a promising diagnostic and prognostic biomarker for OSCC patients.
So far, VEGF-C is considered to be a major pro-lymphangiogenic growth factor that can up-regulate lymphatic vessel density and promote the tumour cells metastasize to lymphatic node. In summary, our present study reports that the level of SMVs is elevated in patients with OSCC, and the increased level of SMVs is closely correlated with the clinical data and outcomes of OSCC patients. Moreover, we also demonstrate that the ratio of apoptotic to non-apoptotic SMVs is significantly decreased in patients with poorly differentiated OSCC. Importantly, lower ratio of apoptotic to non-apoptotic SMVs predicts poorer overall survival of OSCC patients. Taken together, this study highlights the biomarker potential and functional significance of SMVs in OSCC.
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